US 12,419,619 B2
Aspiration device
James Elliott Brown, Killingworth, CT (US); Blake Thomson, Franklin, TN (US); Juliana Xavier-Ferrucio, New Haven, CT (US); Diane Krause, Hamden, CT (US); and Stephanie Halene, New Haven, CT (US)
Assigned to YALE UNIVERSITY, New Haven, CT (US)
Appl. No. 16/344,507
Filed by YALE UNIVERSITY, New Haven, CT (US)
PCT Filed Oct. 24, 2017, PCT No. PCT/US2017/058163
§ 371(c)(1), (2) Date Apr. 24, 2019,
PCT Pub. No. WO2018/081181, PCT Pub. Date May 3, 2018.
Claims priority of provisional application 62/504,090, filed on May 10, 2017.
Claims priority of provisional application 62/411,780, filed on Oct. 24, 2016.
Prior Publication US 2019/0247027 A1, Aug. 15, 2019
Int. Cl. A61B 10/02 (2006.01)
CPC A61B 10/025 (2013.01) [A61B 10/0275 (2013.01); A61B 10/0283 (2013.01); A61B 2010/0258 (2013.01)] 15 Claims
OG exemplary drawing
 
1. An intraosseous method for delivering a pharmacologic composition to mobilize and collect a concentration of stem cells, the method comprising:
inserting an aspiration device into a bone marrow tissue; wherein the aspiration device has at least one elongate member with a lumen extending between a proximal opening and a distal opening;
administering a stem cell mobilizing composition through the distal opening of the at least one elongate member into a first location of the bone marrow tissue;
diffusing the administered stem cell mobilizing composition into a second location of the bone marrow tissue that is remote from the first location of the bone marrow tissue, thereby mobilizing the stem cells in the bone marrow tissue such that the stem cells have an increased concentration at the second location of the bone marrow tissue as compared to prior to the administration of the stem cell mobilizing composition; and
collecting, after a delay of between 30 seconds and 120 minutes from the administration of the stem cell mobilizing composition, a bone marrow tissue sample at the second location of the bone marrow tissue containing the stem cells, wherein a number of stem cells collected is at least 50% greater than compared to a theoretical number of stem cells collected without the administration of the stem cell mobilizing composition into the first location of the bone marrow tissue.